Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aeterna Zentaris (AEZS)

Aeterna Zentaris (AEZS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,256
  • Shares Outstanding, K 1,793
  • Annual Sales, $ 4,500 K
  • Annual Income, $ -16,550 K
  • 60-Month Beta 1.55
  • Price/Sales 2.15
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade AEZS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.64
  • Most Recent Earnings $-4.74 on 05/14/24
  • Next Earnings Date 08/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.07 +12.82%
on 08/05/24
7.54 -24.14%
on 07/09/24
+0.47 (+8.95%)
since 07/08/24
3-Month
3.96 +44.44%
on 06/21/24
11.10 -48.47%
on 05/29/24
-2.08 (-26.67%)
since 05/08/24
52-Week
3.96 +44.44%
on 06/21/24
12.00 -52.33%
on 08/11/23
-6.04 (-51.36%)
since 08/08/23

Most Recent Stories

More News
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline ...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue...

AEZS : 5.72 (+5.93%)
AEZS.TO : 8.29 (+8.08%)

Business Summary

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead...

See More

Key Turning Points

3rd Resistance Point 6.84
2nd Resistance Point 6.52
1st Resistance Point 6.12
Last Price 5.72
1st Support Level 5.40
2nd Support Level 5.08
3rd Support Level 4.68

See More

52-Week High 12.00
Fibonacci 61.8% 8.93
Fibonacci 50% 7.98
Fibonacci 38.2% 7.03
Last Price 5.72
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar